Introduction
Biomarker has been defined as a "characteristic that is objectively measured and evaluated as an indication of normal biologic processes, pathogenic processes, or pharmacological responses to a therapeutic intervention".
1
Use of the term dates back to 1980.
2 In an era called the "biomarker revolution," medical biomarker studies are extremely timely and widely recognized as important. 3 Now there is a multiplicity of biomarker types and applications (Table 1) . 4, 5 From a US regulatory perspective, integration of biomarkers in drug development would help alleviate stagnation and foster innovation in the development of new medical products, leading to more translational and personalized medicine.
6 Biomarker-guided decision making would have a competitive clinical advantage over the existing empirical approach.
7
The first part of this article discusses the unique need for biomarkers in neurological diseases, the importance of cerebrospinal fluid (CSF) as the best source, and the life cycle of the biomarker. It vets the biomarker process and provides tangible steps needed to improve the interpretability of biomarker data for neurological disorders. In the second part, putative CSF cellular immune markers, as revealed by flow cytometric immunophenotyping, are evaluated as candidate biomarkers of neuroinflammation. 8 phenotypes. 9 Although most immunophenotyping studies have been of peripheral blood, only CSF studies are reviewed here.
Biomarkers
Why Are Molecular Biomarkers Uniquely Needed for Neurological Diseases?
Biomarker-guided personalized medicine is not a novel concept, but one applied in most areas of clinical medicine, including some neurological disorders, for years. For example, stroke specialists will investigate and treat all cardiovascular risks factors they can identify, such as hypercoagulable state, sources of embolism, hyperlipidemia, diabetes, and hypertension. Consequently, a patient having a stroke will receive personalized, rational combination of drugs that target simultaneously all risk factors that contribute to a phenotypical expression of their disease. Furthermore, treating physicians will not wait for the second stroke to make necessary therapeutic adjustments; rather they will use normalization of biomarker measurements as a guiding principle. Of course, this strategy required clinical trials that have proven surrogacy of these biomarkers to the clinically relevant outcomes, such as mortality from cardiovascular diseases.
Indeed, molecular biomarkers (ie, clinical laboratory tests) have been assessing functions of different cellular components of the endocrine, hematological, gastrointestinal and immune systems, or cardiomyocytes and renal epithelium for decades. In stark contrast, neurologists lack molecular biomarkers that measure physiological functions (or dysfunctions) of the cellular components of the central nervous system (CNS).
Instead, neurology practice and drug development rely on imaging modalities, especially magnetic resonance imaging (MRI), which provides structural information about CNS tissue. The undisputable utility of MRI in neurology practice makes us often forget that structural imaging does not provide molecular or even cellular information. For example, although brain atrophy reflects loss of CNS tissue, it may be masked for a long time by replacement of one cellular component (eg, neurons) by another (eg, microglia, astroglia, or immune cells) or by alternative processes such as edema or expansion of extracellular matrix. Furthermore, even in the instances when pathologic correlations showed links between certain cellular processes and MRI features, such as perivascular inflammation underlying contrast-enhancing lesions (CELs) in multiple sclerosis (MS), assumptions can be misleading. Assuming that all CELs are inflammatory causes misdiagnosis of ischemic and malignant lesions, 10 while assuming that CELs capture all inflammatory activity underestimates the amount of inflammation, for example, in progressive MS.
11 It is rather common radiology practice to call T2 -FLAIR white matter lesions of a certain size and location "demyelinating," even though this MRI contrast captures differences in the relaxations of hydrogen protons and therefore cannot possibly differentiate one type of tissue integrity change (ie, edema) from another (eg, demyelination or astrogliosis).
12
On the contrary, although clinical deficit correctly reflects loss of cellular functions, it provides limited insight about its reversibility or causes. Additionally, clinical deficit lacks sensitivity, that is, it becomes obvious only after substantial damage to the underlying CNS tissue has accumulated; this is true for virtually any neurological conditions where clinicopathologic correlations exists, including Parkinson disease, primary progressive MS or mild cognitive impairment.
It is reasonable to conclude that this lack of molecular information about CNS tissue is one of the main reasons for the slow therapeutic progress in neurology. Inability to detect earliest stages of CNS diseases prevents initiating treatments at the time when their efficacy is highest. On the contrary, once the clinical defects become apparent, the physiological compensatory processes are exhausted and pathologic processes are well-established and wide-spread. To stop the disease 
